Literature DB >> 29360979

Dissemination of linezolid-dependent, linezolid-resistant Staphylococcus epidermidis clinical isolates belonging to CC5 in German hospitals.

Franziska Layer1, Sophia Vourli2, Vasilios Karavasilis3, Birgit Strommenger1, Konstantina Dafopoulou4, Athanassios Tsakris4, Guido Werner1, Spyros Pournaras2,4.   

Abstract

Objectives: Linezolid-resistant Staphylococcus epidermidis (LRSE) and linezolid-dependent ST22 strains have been shown to predominate in tertiary care facilities all over Greece. We report herein the dissemination of ST22 but also ST2, ST5 and ST168 linezolid-dependent LRSE clones in four unrelated German hospitals.
Methods: Fourteen LRSE clinical isolates recovered during 2012-14 from five distantly located German hospitals were tested by for MIC determination broth microdilution and Etest, PCR/sequencing for cfr and for mutations in 23S rRNA, rplC, rplD and rplV genes, MLST, PFGE and growth curves without and with linezolid at 16 and 32 mg/L.
Results: Most (11, 78.6%) isolates had linezolid MICs >256 mg/L. Five isolates carried the cfr gene. Eight isolates belonged to ST22, two isolates each to ST168 and ST2 and one isolate each to ST5 and ST23. Ten isolates [seven belonging to ST22 and one to each of ST2, ST5 and ST168; all these STs belong to clonal complex (CC) 5] exhibited linezolid-dependent growth, growing significantly faster in linezolid-containing broth. Four isolates were non-dependent (one belonging to each of ST22, ST2, ST23 and ST168). Four isolates came from three different hospitals, whereas four and six isolates were recovered during outbreaks of LRSE in two distinct hospitals. Conclusions: The multi-clonal dissemination of CC5 linezolid-dependent LRSE throughout German hospitals along with the clonal expansion of ST22 linezolid-dependent LRSE in Greek hospitals is of particular concern. It is plausible that this characteristic is inherent and provides a selective advantage to CC5 LRSE under linezolid pressure, contributing to their dissemination throughout hospitals in these countries.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29360979     DOI: 10.1093/jac/dkx524

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  5 in total

1.  Directed evolution of the rRNA methylating enzyme Cfr reveals molecular basis of antibiotic resistance.

Authors:  Kaitlyn Tsai; Vanja Stojković; Lianet Noda-Garcia; Iris D Young; Alexander G Myasnikov; Jordan Kleinman; Ali Palla; Stephen N Floor; Adam Frost; James S Fraser; Dan S Tawfik; Danica Galonić Fujimori
Journal:  Elife       Date:  2022-01-11       Impact factor: 8.140

2.  Emergence of linezolid-resistant Staphylococcus epidermidis in the tertiary children's hospital in Cracow, Poland.

Authors:  Maja Kosecka-Strojek; Ewa Sadowy; Iwona Gawryszewska; Joanna Klepacka; Tomasz Tomasik; Michal Michalik; Waleria Hryniewicz; Jacek Miedzobrodzki
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-04-29       Impact factor: 3.267

3.  Clinical Outcomes Associated With Linezolid Resistance in Leukemia Patients With Linezolid-Resistant Staphylococcus epidermidis Bacteremia.

Authors:  Stephanie A Folan; Kayleigh R Marx; Frank P Tverdek; Issam Raad; Victor E Mulanovich; Jeffrey J Tarrand; Samuel A Shelburne; Samuel L Aitken
Journal:  Open Forum Infect Dis       Date:  2018-07-13       Impact factor: 3.835

4.  Validating a screening agar for linezolid-resistant enterococci.

Authors:  Guido Werner; Carola Fleige; Ingo Klare; Robert E Weber; Jennifer K Bender
Journal:  BMC Infect Dis       Date:  2019-12-23       Impact factor: 3.090

5.  Combined antibiotic stewardship and infection control measures to contain the spread of linezolid-resistant Staphylococcus epidermidis in an intensive care unit.

Authors:  Cihan Papan; Matthias Schröder; Mathias Hoffmann; Heike Knoll; Katharina Last; Frederic Albrecht; Jürgen Geisel; Tobias Fink; Barbara C Gärtner; Alexander Mellmann; Thomas Volk; Fabian K Berger; Sören L Becker
Journal:  Antimicrob Resist Infect Control       Date:  2021-06-30       Impact factor: 4.887

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.